{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-115285","form_type":"8-K","ticker":"DERM","cik":"0001867066","company_name":"Journey Medical Corp","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.198748+00:00","generated_at":"2026-06-08T17:38:38.893092+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Journey Medical reports Q3 2023 net income of $16.8M vs loss a year ago; revenue up 114% YoY to $34.5M","bullets":["GAAP net income $16.8M ($0.80 diluted) vs GAAP net loss $10.1M in Q3 2022.","Total net revenue $34.5M, +114% YoY, including $19.0M upfront from Maruho license for Qbrexza in Asia.","Adjusted EBITDA $20.8M ($0.99 diluted) vs -$4.0M in Q3 2022.","Cost reduction to cut annual SG&A >$17M, surpassing prior $12M target; Q3 SG&A fell 45% to $8.6M.","DFD-29 NDA for rosacea expected to be submitted to FDA around year-end 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-115285","json":"https://secwatch.observer/filing/0001104659-23-115285.json","markdown":"https://secwatch.observer/filing/0001104659-23-115285.md","text":"https://secwatch.observer/filing/0001104659-23-115285.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867066/000110465923115285/0001104659-23-115285-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867066/000110465923115285/tm2330064d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T17:38:38.893092+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"81ceccff6f43976fd7d1dbc6f970d49879856a8c","claim":"Journey Medical Corp reported third quarter ended September 30, 2023 results: revenue $34.5 million, net income $16.8 million, or $0.91 per share basic and $0.80 per share diluted, EPS $0.91 per share basic and $0.80 per share diluted.","evidence_excerpt":"Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights Company generated total net revenues of $34.5 million in the third quarter of 2023, a 101% increase from $17.2 million in the second quarter of 2023 GAAP net income increased to $16.8 million, or $0.91 per share basic and $0.80 per share diluted, for the third quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867066/000110465923115285/0001104659-23-115285-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$34.5 million"},{"label":"Net income","value":"$16.8 million, or $0.91 per share basic and $0.80 per share diluted"},{"label":"EPS","value":"$0.91 per share basic and $0.80 per share diluted"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}